A Phase II international, multicenter study of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma. Hematol Meeting Rep [Internet]. 2009 Jun. 23 [cited 2026 Apr. 18];2(5). Available from: https://journals.pagepress.net/hmr/article/view/725